Video

Dr. Advani Discusses CD30 as a Target in ALCL

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma (ALCL).

The expression of CD30 in ALCL makes it attractive to study for targeted therapies, Advani says. The antibody drug conjugate brentuximab vedotin targets CD30 and is approved by the FDA for relapsed or refractory ALCL. The agent has demonstrated an overall response rate in excess of 80%, including some extremely durable responses.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center